NS Pharma, Inc., a subsidiary of Nippon Shinyaku Co., Ltd., has released preliminary findings from its global Phase 3 clinical trial of NS-065/NCNP-01, commonly known as viltolarsen.

Eupraxia Pharmaceuticals Inc., has received approval from regulators in Australia and Canada to broaden its Phase 1b/2a RESOLVE trial, focusing on EP-104GI as a potential remedy for eosinophilic esophagitis

Coya Therapeutics, Inc., a biotechnology company in the clinical stage, recently completed a Phase 2 study of LD IL-2 in patients with mild-to-moderate Alzheimer's disease. Led by Drs. Stanley Appel and Alireza Faridar at Houston Methodist Hospital, the study

Antion Biosciences, based in Geneva, is at the forefront of cell and gene therapy with its latest breakthrough. They're pioneering the development of next-generation anti-CD19 chimeric antigen receptor

YGION Biomedical GmbH, a company specializing in personalized neoantigen-based cancer vaccines, has successfully completed a Series A financing round, securing €15 million from an Austrian private trust

Imvax, Inc., a biotechnology company specializing in personalized immunotherapies derived from whole tumors, has successfully enrolled participants in its Phase 2b clinical trial for IGV-001, designed for patients

Atara Biotherapeutics, Inc., a leading player in T-cell immunotherapy, has achieved a significant milestone by submitting a Biologics License Application to the U.S. Food and Drug Administration

Rila Therapeutics, a biotech company dedicated to combating chronic fibrotic diseases, has announced the dosing of the first group of subjects in a phase 1 trial of RLA-23174 in China, in collaboration with Yingli Pharmaceutical

Arrowhead Pharmaceuticals, Inc. has announced new interim clinical findings on ARO-RAGE, an RNAi-based therapy designed to treat inflammatory lung conditions such as asthma, during the American Thoracic Society

Drug Farm announced today that the U.S. Food and Drug Administration has given the green light to the Investigational New Drug application for DF-003. This oral alpha-kinase 1